ACADIA to Host Conference Call and Webcast on Monday, May 11, 2009, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--May. 5, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its unaudited financial results for
the first quarter ended March 31, 2009 on Monday, May 11, 2009, after
the U.S. financial markets close. ACADIA's management will host a
conference call and webcast on Monday, May 11, 2009, at 5:00 p.m.
Eastern Time to discuss ACADIA’s financial results and development
programs.
The conference call may be accessed by dialing 866-825-3209 for
participants in the U.S. or Canada and 617-213-8061 for international
callers (reference passcode 62919191). A telephone replay of the
conference call may be accessed through May 25, 2009 by dialing
888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for
international callers (reference passcode 93775458). The conference call
also will be webcast live on ACADIA’s website, www.acadia-pharm.com,
under the investors section and will be archived there until May 25,
2009.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for
central nervous system disorders. ACADIA’s most advanced product
candidates include pimavanserin in Phase III for Parkinson’s disease
psychosis in collaboration with Biovail Laboratories International SRL,
a product candidate in Phase II for chronic pain and a product candidate
in Phase I for glaucoma, both in collaboration with Allergan, as well as
additional compounds in IND-track development. All of the product
candidates in ACADIA’s pipeline emanate from discoveries made using its
proprietary drug discovery platform. ACADIA maintains a website at www.acadia-pharm.com
to which ACADIA regularly posts copies of its press releases as well as
additional information and through which interested parties can
subscribe to receive email alerts.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director,
Investor Relations
Thomas H. Aasen, Vice President and Chief
Financial Officer
(858) 558-2871